Antithrombin III Concentrates

Ménaché, D

doi:10.1016/s0889-8588(18)30298-3

Cited by 11 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En casos en los cuales el paciente se va a ver expuesto a alto riesgo de trombosis, como cirugía, embarazo, parto, etc. se puede usar concentrados de ATIII (10).…”

Section: Discussionunclassified

Ataques Cerebrovasculares isquemicos en Pacientes Jovenes. Reporte de casos y revisión de la literatura.

Casas¹

2013

Rev Med Hered

View full text Add to dashboard Cite

Aunque la incidencia de ataques cerebrovasculares (ACV) isquémicos en personas entre 15 y 50 años , es mucho más baja que la incidencia entre personas mayores de 50 años; no es tan raro encontrar pacientes jóvenes con ACV. El interés de este trabajo es el de presentar con ejemplos de casos reales, ACV en jóvenes (considérese menores de 50 años), y en base a una revisión de la literatura, como enfocar y tratar estos casos.

show abstract

“…En casos en los cuales el paciente se va a ver expuesto a alto riesgo de trombosis, como cirugía, embarazo, parto, etc. se puede usar concentrados de ATIII (10).…”

Section: Discussionunclassified

Ataques Cerebrovasculares isquemicos en Pacientes Jovenes. Reporte de casos y revisión de la literatura.

Casas¹

2013

Rev Med Hered

View full text Add to dashboard Cite

show abstract

“…At this institution, AT-III concentrate was given prophylactically to supplement AT-III levels. It is estimated that each international unit per kilogram body weight administered will raise the plasma activity level by 2% to 2.5% of normal (12). Although AT-III concentrate is prepared from pooled human plasma, it has been heat-treated in solution at 60'C ± 0.5'C which appears to be successful at inactivating hepatitis B and human immunodeficiency viruses (13).…”

Section: Introductionmentioning

confidence: 99%

Supplemental Use of Antithrombin Ill Concentrate in the Pediatric Patient

Cunningham,

Ecklund,

Riley

1996

J Extra Corpor Technol

View full text Add to dashboard Cite

Decreased AT-III levels during cardiopulmonary bypass (CPB) have been observed in pediatric patients and are attributable to hemodilution. Prebypass administration of AT-III to the pediatric patient has been shown to prevent decreases in serum AT-III levels and elevated fibrinopeptide A (FPA) levels before and after bypass. We compared the clinical outcome of patients receiving supplemental AT-III injectate to control patients. Patients with preoperative AT-III levels less than 80% received AT-III injectate prior to heparinization. A retrospective analysis of 149 patients (31 study patients vs. 118 controls) revealed that a greater percentage of patients receiving AT-III were cyanotic (p=0.001) and underwent more complex cardiac repairs (p=0.001). Compared to patients not receiving AT-III, surgeries were performed at lower temperatures (p=0.040) with longer CPB times (p=0.031) and circulatory arrest times (p=0.047). Baseline AT-III levels were significantly lower in the treated group (p<0.0001) but were significantly higher during CPB (p=0.0001). Total postoperative blood loss, blood product administration, rate of reoperation, total time in ICU and mortality proved not to be significantly different between the groups after adjusting for above covariates (p=NS). It appears that maintenance of higher AT-III levels did not affect the clinically measurable outcome variables associated with hemostasis.

show abstract